15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 15 firms covering Palvella Therapeutics, Inc, 15 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $133.00 to $270.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $198.85 sits 39% above the current $143.27. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 14 to 15 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.47 next quarter toward $-6.38 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS15 ratings
Strong Buy
Strong Buy17%
Buy1493%
Hold00%
Sell00%
Strong Sell00%
Based on 15 analysts giving stock ratings to Palvella Therapeutics, Inc.
As of Jul, 15 of 15 firms rate PVLA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PVLA EPS & revenue forecast
EPS · NEXT QUARTER
$-1.47
Range $-1.81 – $-1.05 · 12 analysts · +42% YoY
Next period, 12 analysts expect Palvella Therapeutics, Inc to earn $-1.47 a share (range $-1.81 – $-1.05), versus $-1.03 a year earlier. Full-year consensus is $-5.57, growing to $-6.38 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 12 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $30.6M next year.
Top analysts covering Palvella Therapeutics, Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PVLA.
#1
Andrew Fein
HC Wainwright & Co. · Rank #35
Buy
$270.00+88.5% to target
Overall win rate
46%
+ Follow
#2
Geulah Livshits
Chardan Capital · Rank #100
Buy
$240.00+67.5% to target
Overall win rate
44%
+ Follow
#3
Josh Schimmer
Cantor Fitzgerald · Rank #140
Buy
$200.00+39.6% to target
Overall win rate
38%
+ Follow
#4
JM
Jeet Mukherjee
BTIG
Buy
$215.00+50.1% to target
Coverage
—
+ Follow
#5
WI
Whitney Ijem
Canaccord Genuity
Buy
$227.00+58.4% to target
Coverage
—
+ Follow
PVLA stock forecast FAQ
What is PVLA's average 12-month price target?+
The 13 analysts with a live target average $198.85 for Palvella Therapeutics, Inc over the next 12 months, ranging from a $270.00 high to a $133.00 low.
Is PVLA stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 15 analyst ratings, 15 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for PVLA?+
The Street-high target is $270.00 (HC Wainwright & Co.), and the Street-low is $133.00 (TD Cowen). The average of all 13 active targets is $198.85.
How many Wall Street analysts cover PVLA?+
15 analysts have an active rating on Palvella Therapeutics, Inc, and 13 firms carry a live 12-month price target.
Who is the most accurate analyst covering PVLA?+
Among analysts who currently cover PVLA, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #35). Their current call is Buy with a $270.00 target.
What is Palvella Therapeutics, Inc's projected EPS for next quarter?+
The consensus estimate is $-1.47 per share (range $-1.81 – $-1.05) across 12 analysts. Full-year EPS is projected at $-5.57, rising to $-6.38 the following year.
How much revenue is Palvella Therapeutics, Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $30.6M next year.
Have analysts been upgrading or downgrading PVLA lately?+
As of Jul, 15 of 15 firms rate PVLA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PVLA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
